Metagenomic Analysis of Gut Microbiome in Korean Patients With Ulcerative Colitis

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01010815

Enrollment

Registered

2009-11-10

Start date

2009-11-30

Completion date

2011-11-30

Last updated

2009-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative Colitis

Keywords

ulcerative colitis, gut microbiome, metagenomics

Brief summary

The researchers will investigate gut microbiome in Korean patients with ulcerative colitis and normal control subjects using metagenomic analysis to elucidate the significant difference between two groups This study will help to understand the association between gut microbiome and inflammatory bowel disease.

Interventions

PROCEDUREColonoscopy biopsy

Colonoscopy biopsy will be performed in rectum, ascending and descending colon at study entry

OTHERstool collection

Stool will be collected from participants at study entry

PROCEDUREcolonoscopy biopsy

colonoscopy biopsy will be conducted in rectum, ascending and descending colon from participants 2 times during study - at active phase and inactive phase

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

19 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

* Between the age of 19 and 75 years * willing to consent/undergo necessary procedures * clinically active or inactive Ulcerative colitis

Exclusion criteria

* Inability to provide informed consent or * Clinically severe or fulminant ulcerative colitis * Previous abdominal surgery * Pregnancy * Clinically or laboratory-confirmed gastroenteritis for at least 3 months before sampling * the use of antibiotics in the past a month before sampling * the use of probiotics in the past a month before sampling * Severe cardiovascular or pulmonary disease * Severe convulsive disorder and current use of anti-convulsive medication * Malignancy * Transplantation

Design outcomes

Primary

Measure	Time frame
characterize the difference in gut microbiomes through metagenomic analysis between UC patients and normal control subjects	1 year

Secondary

Measure	Time frame
characterize the difference in gut microbiomes through metagenomic analysis between stool specimens and biopsy specimens in participants with UC and normal subjects	1 year
characterize the difference in gut microbiomes among colonoscopy biopsy locations (rectum, ascending and descending colon)	1 year
characterize the difference in gut microbiomes between active and inactive UC patients	1 year

Countries

South Korea

Contacts

Primary ContactJoo Sung Kim, M.D., PhD

jooskim@snu.ac.kr+82-2-740-8112

Backup ContactSeong-Joon Koh, M.D.

jel1206@medimail.co.kr+82-2-740-8112

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026